Phase IA Trial of Intrathecal Administration of Human Umbilical Cord Blood-Derived Cell Therapy (DUOC-01) in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS). DUOC-01 is a population of cells expanded from donated human umbilical cord blood cells and is intended for treatment of neurodegenerative and demyelinating diseases. There will be approximately 20 participants enrolled. Exploratory objectives include changes in MS assessment scores, changes in brain MRI findings, and changes in blood biomarkers.
• Male and female subjects must be 18-65 years of age
• Diagnosis of primary progressive MS according to 2017 revised McDonald criteria (26)
• EDSS score at screening 3.0-6.5 that was not acquired within the last 6 months
• Stable disease state as evidenced by no significant change in EDSS (1 point or more) in the last 3 months
• Patients must have a suitably matched, banked UCB per section 5.3
• Able to complete a written informed consent prior to any study assessments
• Patients of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after DUOC-01 dosing so that, in the opinion of the Investigator, they will not become pregnant during the course of the study.
• Patient is a good candidate for the trial, in the opinion of the Investigators
• Subjects on disease-modifying therapies upon entering the study must continue on these therapies as a concomitant treatment throughout the course of the study to minimize additional variables. However, changes in these disease-modifying therapies can occur at the clinician's discretion, if there are clinical reasons to do so, which would be documented.